Sotorasib
- CAS No.2296729-00-3:
- MF:C30H30F2N6O3:
- MW:560.6:
- Reference standard: In-House:
- Documentation:TP:
- Inquiry
Product Description
Sotolacib, an acrylamide-derived KRAS inhibitor, was developed by Amgen and is currently in clinical trials for the treatment of solid tumors with KRAS G12C mutations. This mutation accounts for more than 50% of all KRAS mutations. It is the first experimental KRAS inhibitor. The drug currently in development [MRTX849] has the same target.
Hits: 【Print】